Jiangsu Lianhuan Pharmaceutical Co Ltd: Market Activity and Industry Trends

Jiangsu Lianhuan Pharmaceutical Co., Ltd., a healthcare company operating in the pharmaceutical industry, is listed on the Shanghai Stock Exchange. As of July 10, 2025, the company’s close price was 14.98 CNH, matching its 52-week high, with a 52-week low of 7.71 CNH recorded on July 24, 2024. The company has a market capitalization of 3,890,000,000 CNH and a price-to-earnings ratio of 52.07.

Innovative Drug Sector Activity

Recent market activity has highlighted the innovative drug sector, with companies like New Tianyao Pharmaceutical and Lianmei Pharmaceutical experiencing significant gains. On July 14, 2025, New Tianyao Pharmaceutical surged to a halt, while Lianmei Pharmaceutical’s 20CM stock also hit a halt. Other companies such as Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and Yaxing Pharmaceutical saw increases of over 15%. This surge is attributed to the official launch of adjustments to the national basic medical insurance, maternity insurance, and work injury insurance drug catalogs, as well as the commercial health insurance innovative drug catalog. Eligible applicants can submit their applications online through the national medical insurance service platform from July 11 to 20, 2025.

Market Focus and Institutional Research

In the past week, over 200 stocks were subject to institutional research, with Leksin Technology receiving the most attention. On average, stocks researched by institutions increased by 2.2%. Notably, Lianhuan Pharmaceutical, New Ya Electronics, Zhongzheng Hanwang, and Zhongyi Technology each saw increases of over 20%.

Lianhuan Pharmaceutical’s Market Performance

Lianhuan Pharmaceutical has been a focal point in the market, with its stock experiencing a significant rise. On July 11, 2025, the company issued a public announcement regarding abnormal trading volatility. The company has held four institutional research activities in July alone, with a cumulative increase of 49% since the beginning of the month. This reflects the heightened interest in the innovative drug concept.

Conclusion

The innovative drug sector continues to attract significant attention, with regulatory adjustments and institutional research driving market activity. Companies like Jiangsu Lianhuan Pharmaceutical Co Ltd are at the forefront of this trend, benefiting from increased investor interest and favorable market conditions.